Barclays PLC Increases Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Barclays PLC lifted its position in Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 421.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,554 shares of the company's stock after purchasing an additional 86,933 shares during the quarter. Barclays PLC owned about 0.15% of Schrödinger worth $1,995,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. KBC Group NV lifted its position in Schrödinger by 45.4% during the third quarter. KBC Group NV now owns 2,508 shares of the company's stock valued at $47,000 after purchasing an additional 783 shares during the last quarter. Quarry LP raised its position in shares of Schrödinger by 1,150.0% during the 3rd quarter. Quarry LP now owns 2,825 shares of the company's stock valued at $52,000 after buying an additional 2,599 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Schrödinger in the 2nd quarter valued at about $66,000. Quest Partners LLC grew its position in Schrödinger by 1,005.6% in the second quarter. Quest Partners LLC now owns 4,555 shares of the company's stock worth $88,000 after acquiring an additional 4,143 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Schrödinger during the third quarter worth approximately $102,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Schrödinger

In other Schrödinger news, insider Margaret Dugan sold 1,531 shares of the company's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the sale, the insider now directly owns 13,469 shares in the company, valued at approximately $239,478.82. This represents a 10.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.60% of the company's stock.

Analyst Ratings Changes

Separately, BMO Capital Markets raised their price objective on Schrödinger from $25.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.90.

Schrödinger Trading Down 2.6 %

Shares of SDGR stock traded down $0.53 on Friday, reaching $19.77. 686,731 shares of the company's stock were exchanged, compared to its average volume of 748,725. The company's fifty day simple moving average is $20.02 and its 200 day simple moving average is $19.99. The stock has a market capitalization of $1.44 billion, a PE ratio of -8.45 and a beta of 1.56. Schrödinger, Inc. has a 52 week low of $16.67 and a 52 week high of $37.48.

Schrödinger (NASDAQ:SDGR - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.12). The company had revenue of $35.30 million for the quarter, compared to analysts' expectations of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm's revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.86) earnings per share. As a group, sell-side analysts predict that Schrödinger, Inc. will post -2.29 earnings per share for the current fiscal year.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.